{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-016717","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2026-05-13T20:05:56+00:00","discovered_at":"2026-05-13T20:07:00.323726+00:00","generated_at":"2026-05-13T22:08:33.893915+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aytu BioPharma Q3 net loss $5.6M; EXXUA launch revenue $2.4M","bullets":["Net revenue $12.4M, down 33% YoY from $18.5M; net loss $5.6M vs net income $4.0M.","EXXUA (gepirone) contributed $2.4M net revenue; over 1,300 prescriptions from 450 prescribers in partial quarter.","ADHD Portfolio $9.1M (-41% YoY) due to sales force shift to EXXUA and generic competition for Adzenys XR-ODT.","Adjusted EBITDA -$2.8M vs $3.9M YoY; warrant amendment reduced derivative liabilities by $26.4M, boosting equity.","Cash $26.7M at March 31, 2026, down from $31.0M at June 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016717","json":"https://secwatch.observer/filing/0001437749-26-016717.json","markdown":"https://secwatch.observer/filing/0001437749-26-016717.md","text":"https://secwatch.observer/filing/0001437749-26-016717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926016717/0001437749-26-016717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926016717/aytu20260209_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:08:33.893915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}